Boehringer Ingelheim and Eli Lilly and Company received Marketing Authorisation from the European Commission for Jentadueto which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet.
URL: http://www.news-medical.net/news/20120725/EC-grants-Marketing-Authorisation-to-Boehringer-Ingelheim-and-Lillye28099s-Jentadueto-for-diabetes.aspx
No comments:
Post a Comment